Clifford Bechtold

702 total citations
17 papers, 462 citations indexed

About

Clifford Bechtold is a scholar working on Infectious Diseases, Virology and Molecular Biology. According to data from OpenAlex, Clifford Bechtold has authored 17 papers receiving a total of 462 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 8 papers in Virology and 6 papers in Molecular Biology. Recurrent topics in Clifford Bechtold's work include HIV Research and Treatment (8 papers), HIV/AIDS drug development and treatment (8 papers) and HIV/AIDS Research and Interventions (4 papers). Clifford Bechtold is often cited by papers focused on HIV Research and Treatment (8 papers), HIV/AIDS drug development and treatment (8 papers) and HIV/AIDS Research and Interventions (4 papers). Clifford Bechtold collaborates with scholars based in United States, Belgium and Switzerland. Clifford Bechtold's co-authors include P F Lin, R.E. Rose, Richard J. Colonno, Masud Alam, Amy K. Patick, Irfan Qureshi, Himadri Samanta, Giridhar Tirucherai, Michael K. Ahlijanian and Michael Grundman and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Neurology and Journal of Virology.

In The Last Decade

Clifford Bechtold

17 papers receiving 440 citations

Peers

Clifford Bechtold

VIROL

PHYSI

EPIDE

Charvi Patel United States

Kumar Srinivasan United States

J Chodakewitz United States

Luxshimi Lal Australia

Ken Williams United States

Sarah Corey United States

Andrea Rubio Argentina

Eugene L. Asahchop Canada

Adeline Nukuna United States

Shetty Ravi Dyavar United States

Charvi Patel United States

Clifford Bechtold

349 ×1.1

VIROL

147 ×0.5

130 ×1.5

33 ×0.5

PHYSI

57 ×1.3

EPIDE

Citations per year, relative to Clifford Bechtold Clifford Bechtold (= 1×) peers Charvi Patel

Countries citing papers authored by Clifford Bechtold

Since Specialization

Citations

This map shows the geographic impact of Clifford Bechtold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clifford Bechtold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clifford Bechtold more than expected).

Fields of papers citing papers by Clifford Bechtold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clifford Bechtold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clifford Bechtold. The network helps show where Clifford Bechtold may publish in the future.

Co-authorship network of co-authors of Clifford Bechtold

This figure shows the co-authorship network connecting the top 25 collaborators of Clifford Bechtold. A scholar is included among the top collaborators of Clifford Bechtold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clifford Bechtold. Clifford Bechtold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Servais, Laurent, Lindsey Lair, Anne M. Connolly, et al.. (2024). Taldefgrobep Alfa and the Phase 3 RESILIENT Trial in Spinal Muscular Atrophy. International Journal of Molecular Sciences. 25(19). 10273–10273. 8 indexed citations

Lair, Lindsey, Irfan Qureshi, Clifford Bechtold, et al.. (2024). The Phase 3 RESILIENT Study: Taldefgrobep Alfa in Spinal Muscular Atrophy (P2-11.008). Neurology. 102(7_supplement_1). 2 indexed citations

Lair, Lindsey, Irfan Qureshi, Clifford Bechtold, et al.. (2023). P04 Taldefgrobep alfa: preclinical and clinical data supporting the phase 3 RESILIENT study in spinal muscular atrophy. Neuromuscular Disorders. 33. S163–S163. 4 indexed citations

Wagner, Kathryn R., Brenda Wong, Barry J. Byrne, et al.. (2018). A randomized, placebo-controlled, double-blind, Phase 1b/2 study of the novel antimyostatin adnectin RG6206 (BMS-986089) in ambulatory boys with Duchenne muscular dystrophy (P5.431). Neurology. 90(15_supplement). 3 indexed citations

Wong, Beatrix, Bryan Byrne, H. Lee Sweeney, et al.. (2018). DMD CLINICAL THERAPIES I. Neuromuscular Disorders. 28. S66–S66. 1 indexed citations

Qureshi, Irfan, Giridhar Tirucherai, Michael K. Ahlijanian, et al.. (2018). A randomized, single ascending dose study of intravenous BIIB092 in healthy participants. Alzheimer s & Dementia Translational Research & Clinical Interventions. 4(1). 746–755. 69 indexed citations

Boxer, Adam L., Irfan Qureshi, Michael Grundman, et al.. (2018). Multiple Ascending Dose Study of the Tau-Directed Monoclonal Antibody BIIB092 in Patients with Progressive Supranuclear Palsy (S27.004). Neurology. 90(15_supplement). 4 indexed citations

Dam, Tien, Adam L. Boxer, Lawrence I. Golbe, et al.. (2018). Efficacy and Safety of BIIB092 in Patients with Progressive Supranuclear Palsy: PASSPORT Phase 2 Study Design (P6.073). Neurology. 90(15_supplement). 5 indexed citations

Jacobsen, Leslie K., Clifford Bechtold, Giridhar Tirucherai, Michael K. Ahlijanian, & Feng Luo. (2016). BMS-986089: A novel adnectin protein that dose dependently lowers free myostatin and increases muscle volume and lean body mass. Neuromuscular Disorders. 26. S95–S95. 6 indexed citations

10.

Deminie, Carol, Clifford Bechtold, David Stock, et al.. (1996). Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrobial Agents and Chemotherapy. 40(6). 1346–1351. 39 indexed citations

11.

Rose, R.E., Ying Gong, Clifford Bechtold, et al.. (1996). Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.. Proceedings of the National Academy of Sciences. 93(4). 1648–1653. 99 indexed citations

12.

Lin, P F, Himadri Samanta, Clifford Bechtold, et al.. (1996). Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor. Antimicrobial Agents and Chemotherapy. 40(1). 133–138. 39 indexed citations

13.

Bechtold, Clifford, Amy K. Patick, Masud Alam, et al.. (1995). Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease. Antimicrobial Agents and Chemotherapy. 39(2). 374–379. 12 indexed citations

14.

Patick, Amy K., R.E. Rose, Clifford Bechtold, et al.. (1995). Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. Journal of Virology. 69(4). 2148–2152. 51 indexed citations

15.

Lin, P F, Himadri Samanta, R.E. Rose, et al.. (1994). Genotypic And Phenotypic Analysis Of Human Immunodeficiency Virus Type 1 Isolates From Patients On Prolonged Stavudine Therapy. The Journal of Infectious Diseases. 170(5). 1157–1164. 108 indexed citations

16.

Samanta, Himadri, R.E. Rose, Amy K. Patick, et al.. (1994). Characterization of a Mutant HIV-1 Reverse Transcriptase Resistant to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)-imidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150). Antiviral chemistry & chemotherapy. 5(4). 278–281. 3 indexed citations

17.

Alam, Masud, Clifford Bechtold, Amy K. Patick, et al.. (1993). Substituted naphthalenones as a new structural class of HIV-1 reverse transcriptase inhibitors. Antiviral Research. 22(2-3). 131–141. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact